The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration - Takeaways - MDSpire

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

  • By

  • Aleksander Dominikowski

  • Zofia Rękoś

  • Michał Olejarz

  • Ewelina Szczepanek-Parulska

  • Remigiusz Domin

  • Marek RuchaŁa

  • June 18, 2026

  • 0 min

Share

  • 1

    Performance-enhancing peptides (PEPs) target the GH-IGF-1 axis and are often used off-label for physique and performance enhancement.

  • 2

    Commonly used PEPs include GHRH analogues, GHS, GH fragments, and IGF-1 analogues, with varying levels of clinical evidence.

  • 3

    Adverse effects of PEPs can include endocrine disturbances, fluid retention, musculoskeletal symptoms, and injection-site reactions.

  • 4

    The use of PEPs is often driven by aesthetic goals and muscle dysmorphia, leading individuals to bypass clinical oversight.

  • 5

    Clinicians require a framework to assess symptoms and risks associated with PEP use due to the lack of regulatory approval and robust data.

Original Source(s)

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

  • by Aleksander Dominikowski, Zofia Rękoś, Michał Olejarz, Ewelina Szczepanek-Parulska, Remigiusz Domin, Marek RuchaŁa

  • June 18, 2026

Related Content

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

Case Report: Subcutaneous sensor-augmented insulin pump therapy in a 510-g preterm infant with hyperglycemia

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.